HSG Blog

Loss of our friend, Dr. Kimberly Quaid de Cordon

We heard today that Kimberly Quaid de Cordon, PhD, died in a tragic accident, and we now are mourning the loss...

Welcome new staff member, members of leadership team

The Huntington Study Group is pleased to announce a new staff member and new members of the leadership team. Anne...

Overnight Switch from Tetrabenazine to Deutetrabenazine Safe, Trial Shows

JAMA Neurology paper published today from ARC-HD Trial People with Huntington disease-associated chorea can safely convert overnight from tetrabenazine to...

HD Insights Volume 17 (PDF)

For a non-PDF version of HD Insights Vol. 17, click here.

FDA approves deutetrabenazine (AUSTEDO™) to treat chorea

On April 3, 2017, the FDA approved a new drug, deutetrabenazine, to treat HD-associated chorea. By: Sara LaJeunesse, MSc Deutetrabenazine...

Meet the Scientist : Beverly Davidson

VITAL SIGNS NAME: Beverly Davidson, PhD TITLE: Chief Scientific Strategy Officer at the Children’s Hospital of Philadelphia (CHOP); Director of...

Game-changing gene-silencing therapies for HD

VITAL SIGNS NAME: Amber Southwell, PhD TITLE: Assistant Professor of Neuroscience, Burnett School of Biomedical Sciences, University of Central Florida...

Research Round-Up

By: Lise Munsie, PhD In neurons… The HD Induced Pluripotent Stem Cell (iPSC) consortium differentiated HD patient iPSCs into neuronal...

Highlights of CHDI

The 12th Annual CHDI HD Therapeutics Conference was held in St. Julian’s, Malta, April 24–27, 2017. By: Nicholas Caron, PhD...

HD Research Around the World: Brazil

By: Irina Kerkis, PhD Little is known formally about the exact number of HD patients and individuals at risk in...

1 2 3 21